injury

Depo-Provera Brain Tumor Symptoms

Preparing your case review…
Written By
People's Justice Legal Research Team

Warning Signs of a Meningioma

Meningiomas are slow-growing tumors, and symptoms may develop over months or years. The most common symptoms include: persistent headaches that worsen over time (experienced by the majority of patients), vision problems (blurred vision, double vision, partial vision loss), seizures (occurring in over one-third of patients), hearing loss or ringing in the ears (tinnitus), and weakness or numbness in the arms or legs.

Symptoms by Tumor Location

Symptoms vary depending on where the meningioma develops. Convexity meningiomas (top of brain) cause seizures and focal weakness. Parasagittal meningiomas cause leg weakness and seizures. Sphenoid wing meningiomas cause visual problems and facial pain. Posterior fossa meningiomas cause balance problems and hearing loss. Olfactory groove meningiomas cause loss of smell.

When to Seek Imaging

If you received Depo-Provera injections and experience new or worsening headaches, any visual changes, a seizure, unexplained weakness or numbness, or cognitive changes, request a contrast-enhanced MRI of the brain from your healthcare provider. Early detection improves treatment outcomes and strengthens your legal claim.

Documenting Your Symptoms

For both medical and legal purposes, keep a detailed symptom diary recording: when symptoms started, frequency and severity, how symptoms affect daily activities, all medical appointments and imaging results, and timeline of Depo-Provera use. This documentation is critical evidence in your case.

Research & Evidence

Scientific Evidence

Medroxyprogesterone Acetate and Meningioma: A Global Issue

Roland N, Froelich S, Weill A (2025). Frontiers in Global Womens Health

View on PubMed

Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial Meningioma

Roland N, Neumann A, Hoisnard L, Gagne JJ, Froelich S, Weill A (2024). The BMJ

View on PubMed

The Association between Medroxyprogesterone Acetate Exposure and Meningioma

Griffin BR et al. (2024). Cancers

View on PubMed
FAQ

Frequently Asked Questions

See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
Related Topics

Related Pages

Depo-Provera Meningioma Brain Tumor

Meningioma — a tumor in the tissue surrounding the brain — is the primary injury in Depo-Provera lawsuits. Studies show long-term users face up to a 5.6x increased risk. The tumor can cause seizures, vision loss, and require major brain surgery.

meningiomabrain-tumorprogesterone-receptor
Learn more

Depo-Provera Long-Term Use Risks

Long-term Depo-Provera use carries multiple serious risks: meningioma brain tumors (up to 5.6x risk), significant bone density loss (black box warning), weight gain, depression, and delayed return to fertility. The FDA recommends limiting use to 2 years.

long-term-usebone-densitycumulative-risk
Learn more

Depo-Provera Settlement Amounts

No Depo-Provera meningioma cases have settled or gone to trial yet. Projected settlements based on comparable pharmaceutical brain injury litigation suggest $75,000 to $1.5 million+ depending on injury severity.

settlement-amountsprojected-valuesmdl-3140
Learn more

Pfizer Depo-Provera Lawsuit

Pfizer inherited Depo-Provera when it acquired Pharmacia & Upjohn in 2002. Despite international warnings dating to 2015, Pfizer did not add a U.S. meningioma warning until December 2025. Plaintiffs allege a pattern of delayed safety action prioritizing revenue over patient safety.

pfizerpharmaciaupjohn
Learn more

Depo-Provera Alternatives After Diagnosis

If you are diagnosed with a meningioma, the FDA recommends discontinuing Depo-Provera immediately. Safer contraceptive alternatives exist that do not carry meningioma risk, including copper IUDs, barrier methods, and non-progestin options.

alternativescontraceptioncopper-iud
Learn more

Depo-Provera Military Veterans

Military women were disproportionately prescribed Depo-Provera due to its convenience for deployment. If you received Depo-Provera during military service and were later diagnosed with a meningioma, you may be eligible for both civil lawsuit compensation and VA benefits.

militaryveteransdeployment
Learn more

Depo-Provera MRI Screening

Current guidelines do not recommend routine MRI screening for asymptomatic Depo-Provera users. However, the updated FDA label instructs providers to monitor for meningioma symptoms. If you have symptoms, request brain imaging immediately.

mri-screeningbrain-imagingearly-detection
Learn more
Parent Case

Depo-Provera Brain Tumor Lawsuits Lawsuit

Depo-Provera (medroxyprogesterone acetate / MPA) is a contraceptive injection administered every three months. Over 2,000 lawsuits consolidated in MDL 3140 in the Northern District of Florida allege that Pfizer failed to warn about a significantly elevated risk of meningioma — a tumor in the tissue surrounding the brain and spinal cord. Women who received the shot for more than one year face up to a 5.6-fold increased risk, and the risk escalates with duration of use.

View full case overview